share_log

What's Going On With Recursion Pharmaceuticals Stock Monday?

What's Going On With Recursion Pharmaceuticals Stock Monday?

周一,Recursion药品股票怎么了?
Benzinga ·  06/24 17:12

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares traded higher Monday after the company provided updated guidance and partnership updates at its Investor Day. The stock is continuing to move higher after hours amid a CNBC appearance from CEO Christopher Gibson.

Recursion Pharmaceuticals Inc(NASDAQ: RXRX)股票在投资者日提供更新的指引和合作伙伴更新后交易上涨。在CNBC首席执行官Christopher Gibson的露面之后,股票在交易时段继续上涨。

What Happened: Recursion provided updated pipeline guidance to investors, analysts and other stakeholders during its Download Day on Monday. The event featured a number of prominent speakers, including NVIDIA Corp (NASDAQ:NVDA) founder and CEO Jensen Huang.

发生了什么:Recursion在Monday的Download Day上向投资者、分析师和其他利益相关者提供了更新的流水线指导。该活动邀请了许多知名的演讲者,包括英伟达创始人兼CEOJensen Huang。

The stock appears to be moving higher in extended trading after Gibson went on CNBC's "Closing Bell: Overtime" just "minutes" before he was set to take the stage with Huang to discuss the role AI will play in drug discovery and development in the future.

股票似乎在盘后交易中上涨,此前Gibson在CNBC“收盘钟:加班”节目中出现,只有“几分钟”就要与Huang一起上台,讨论AI在未来药物发现和开发中发挥的作用。

Gibson also highlighted that Recursion has built the most powerful supercomputer in the biotech space with the help of Nvidia: BioHive-2.

Gibson还强调,Recursion在Nvidia的帮助下建立了生物技术领域中最强大的超级计算机:BioHive-2。

"We've been able to demonstrate that using these tools, we can roughly three times the speed of discovering and developing medicines towards the clinic and dramatically reduce the costs," Gibson said on the show.

“我们已经能够证明,使用这些工具,我们可以将发现和开发药物的速度提高大约三倍,并大幅降低成本,”吉布森在节目中说。

"Ultimately, the most important lever is going to be improving the probability of success ... 90% of drugs that go into clinical trials today fail ... and it's because biology is so complex and machine learning and AI are the right tools when you bring the right data and the right compute to bear to help us make sense and really decode biology."

“最重要的杠杆最终将是提高成功的概率...今天进入临床试验的药物有90%无法成功...这是因为生物学是如此复杂,当您提供正确的数据和正确的计算方式来帮助我们理解和解码生物学时,机器学习和AI是正确的工具。”

Nvidia reported investments in multiple companies, including Recursion Pharmaceuticals, in a 13-F filing with the SEC earlier this year. According to the filing, Recursion is Nvidia's second-largest investment after Arm Holdings.

Nvidia在今年早些时候提交给SEC的13-F文件中报告了对多家公司的投资,包括Recursion Pharmaceuticals。根据该文件,Recursion是Nvidia在Arm Holdings之后的第二大投资。

RXRX Price Action: Recursion Pharmaceuticals shares were up 4.50% after hours at $9.34 at the time of publication, according to Benzinga Pro.

RXRX股票价格行情:根据Benzinga Pro的数据,在发布时,Recursion Pharmaceuticals的股票在盘后交易中上涨了4.50%,为9.34美元。

Photo: 3844328 from Pixabay.

照片来自Pixabay(ID:3844328)。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发